Janssen Biotech discontinued development of prizloncabtagene autoleucel (C-CAR039), an anti-CD20/CD19 bispecific CAR T therapy, prompting Abelzeta Pharma to regain rights. Abelzeta previously licensed global rights excluding China to Janssen in a deal reportedly worth $245 million. The discontinuation shifts the asset back to Abelzeta’s control, potentially changing the therapy’s development strategy, trial plans, and partnership landscape. For Janssen, the exit reflects ongoing portfolio prioritization and the reality that CAR-T pipelines must balance efficacy, manufacturing complexity, and market economics. For Abelzeta, reclaiming the program could enable a faster path to new partnering opportunities, depending on prior clinical data packages and regulatory engagements.